Allan L.
- Country
- Denmark
- Department
- Pediatrics and Clinical Genetics
Research Overview
- Phase 1 First‑in‑Human Study of the Phenylalanine‑Binding Polymer Phelimin in Healthy Volunteers and Adults With Classical Phenylketonuria
- An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to <18 Years
- Phase 3 Open-Label Evaluation of PTC923 (Sepiapterin) for Long-Term Safety and Dietary Impact in Phenylketonuria Patients
Data & Insights
Has run more than one trial at 6 of 32 partner sites.
Specializations
Metabolic Disease Management
The investigator specializes in treating phenylketonuria (PKU), focusing on innovative therapeutic approaches for managing this inherited metabolic disorder. Their work explores dietary management strategies and novel treatment options for patients with PKU.
- Phenylketonuria treatment optimization
- Dietary phenylalanine management
- Long-term metabolic control
Genetic Storage Disorders
Expertise in treating Glycogen Storage Disease Type Ia, with particular focus on gene therapy approaches. The investigator studies innovative treatments aimed at improving glucose control and reducing dependence on external glucose supplementation.
- Gene therapy applications
- Glucose homeostasis management
- Metabolic pathway regulation
Lipid Disorders
Specialized focus on pediatric heterozygous familial hypercholesterolemia (HeFH), investigating therapeutic interventions for young patients. The investigator's work encompasses evaluation of new treatment approaches for managing cholesterol levels in children and adolescents.
- Pediatric lipid management
- Familial hypercholesterolemia treatment
- Cardiovascular risk prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.